FindTrial
Sign In

Prognostic markers in Breast cancer

"ESTROGEN, PROGESTERONE AND HER-2/neu STATUS IN BREAST CARCINOMA: COMPARISON OF IMMUNOCYTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY.â??

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/03/004455
Enrollment
30
Registered
2014-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Mastectomy specimen of breast cancer

Interventions

Control Intervention1: immunohistochemistry, immunocytochmistry: immunocytochemistry is done on the scrape smears of breast tumors and compared with the immunohistochemistry on the corresponding histo

Sponsors

FR MULLER MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patients with primary carcinoma of breast undergoing surgery in Father Muller Medical college.

Exclusion criteria

Exclusion criteria: •The patients whose specimens are fixed in formalin. •Necrotic and highly desmoplastic tumors with scanty cellularity. •Extensive in situ comedo component. •Mucinous carcinomas.

Design outcomes

Primary

MeasureTime frame
To evaluate the degree of correlation between immunocytochemistry (ICC) and immunohistochemistry (IHC) of ER, PR and HER-2/neu in Breast cancer.Timepoint: 2years—

Secondary

MeasureTime frame
to determine the role of scrape cytology in immunocytochemistryTimepoint: 2years—

Countries

India

Contacts

Public ContactDr SUBHAN ALI R

FR. MULLER MEDICAL COLLEGE, KANKANADY, MANGALORE â?? 575002

hilda67@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026